Ustekinumab and Anti-Ustekinumab Antibody
Desired Epic Build
* = editable field
| Cerner Primary Mnemonic: | Ustekinumab & Anti-Ustekinumab Ab | |||||||||
| PDM | 235038 | |||||||||
| Informatics - Workgroup | Chemistry | |||||||||
| Synonyms * | USTEKINUMAB UST Ustekinumab & Anti-Ustekinumab Ab | |||||||||
| Display Name * | Ustekinumab and Anti-Ustekinumab Antibody | |||||||||
| Specimen Sources (combined Order Entry and Specimen Navigator) * | ||||||||||
| Specimen Types (combined Order Entry and Specimen Navigator) * | ||||||||||
| Body Fluids (types sent through AOEs) | ||||||||||
| Specimen Navigator Specimen Types | ||||||||||
| Specimen Navigator Specimen Sources | ||||||||||
| Specimen Navigator Short Name | ||||||||||
| Ordering info (EPIC SmartText) | rovides ustekinumab drug concentration and anti‐ustekinumab antibodies in order to optimize treatment and facilitate clinical decision‐making. This assay may be helpful in any patients on ustekinumab therapy for Crohn's disease, psoriasis, or other autoimmune conditions. Limitations Drug concentration should be interpreted with confirmation of specimen collection timing. Non‐trough concentrations may be misleading. Trough blood collection (just before or within 24 hrs. of next dose) is suitable because target ranges and therapeutic cut‐offs have been established in clinical studies using trough concentration. The drug half‐life should be taken into consideration when interpreting results from non‐perfect trough collections. Some primary non‐responders have inadequate clinical response despite adequate trough levels. As with other biologics, the optimal ustekinumab concentration depends upon patient‐specific factors including co‐morbidities, disease and desired therapeutic endpoint. Positive anti‐ustekinumab antibodies should be interpreted in the context of the concomitant free ustekinumab drug level. High serum biotin concentrations in patients taking biotin supplements may cause an interference in this assay. Patients may be advised to stop biotin consumption at least 72 hours prior to sample collection. | |||||||||
| IP Orderable (inpatient) | Yes | |||||||||
| OP Orderable (outpatient) | Yes | |||||||||
| AOEs * | ||||||||||
| AP AOEs | ||||||||||
| Special History | No | |||||||||
| Build Comments | ||||||||||
| Filter * | ||||||||||
| Cerner Site Restrict | LabCorp | |||||||||
Cerner Results
| ||||||||||
Actual Epic Build 3/11/2025
| PROCEDURE ID | 182907 | ||||||||||||||||||
| PDM | 235038 | ||||||||||||||||||
| ORDER DISPLAY NAME | Ustekinumab and Anti-Ustekinumab Antibody | ||||||||||||||||||
| PROCEDURE NAME | USTEKINUMAB AND ANTI-USTEKINUMAB ANTIBODY | ||||||||||||||||||
| PROCEDURE MASTER NUMBER | LAB14021 | ||||||||||||||||||
| SHORT PROCEDURE NAME | USTEKINUMAB & ANTI-USTEKINUMAB AB | ||||||||||||||||||
| CATEGORY CODE | 1.0 | ||||||||||||||||||
| CATEGORY CODE RECORD NAME | LAB BLOOD ORDERABLES | ||||||||||||||||||
| SYNONYMS | USTEKINUMAB UST Ustekinumab & Anti-Ustekinumab Ab |
||||||||||||||||||
| CLINICALLY ACTIVE | Yes | ||||||||||||||||||
| ORDERABLE | Yes | ||||||||||||||||||
| PERFORMABLE | Yes | ||||||||||||||||||
| FILTER GENOMICS | |||||||||||||||||||
| REFERENCE LINK URL | https://labs.northwell.edu/epic/test/182907 | ||||||||||||||||||
| ORDERING INSTRUCTIONS | |||||||||||||||||||
| DEFAULT SPECIMEN TYPE | Blood | ||||||||||||||||||
| SPECIMEN TYPE PICK LIST | Blood | ||||||||||||||||||
| SPECIMEN TYPE LIST | |||||||||||||||||||
| OP SPECIMEN TYPE LIST | |||||||||||||||||||
| SPECIMEN SOURCE PICK LIST | Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous |
||||||||||||||||||
| SPECIMEN SOURCE DEFAULT - MALE | Blood, Venous | ||||||||||||||||||
| SPECIMEN SOURCE DEFAULT - FEMALE | Blood, Venous | ||||||||||||||||||
| SPECIMEN SOURCE LIST | |||||||||||||||||||
| OP SPECIMEN SOURCE LIST | |||||||||||||||||||
| IP LAB TEST COMPONENTS FOR REPORT | USTEKINUMAB ANTIUSTAB |
||||||||||||||||||
| OP LAB TEST COMPONENTS FOR REPORT | USTEKINUMAB ANTIUSTAB |
||||||||||||||||||
| ORDER QUESTIONS | [] | ||||||||||||||||||
| ORDER QUESTIONS RECORD NAME | |||||||||||||||||||
| INPATIENT ORDER QUESTIONS | [] | ||||||||||||||||||
| INPATIENT ORDER QUESTIONS RECORD NAME | |||||||||||||||||||
| ORDER SPECIFIC QUESTION OVERRIDE | |||||||||||||||||||
| INPATIENT QUESTION OVERRIDE | |||||||||||||||||||
| LOCATION RESTRICT LIST IP | |||||||||||||||||||
| LOCATION RESTRICT LIST IP RECORD NAME | |||||||||||||||||||
| LOCATION RESTRICT LIST INCLUDE IP | |||||||||||||||||||
| LOCATION RESTRICT LIST OP | |||||||||||||||||||
| LOCATION RESTRICT LIST OP RECORD NAME | |||||||||||||||||||
| LOCATION RESTRICT LIST INCLUDES OP | |||||||||||||||||||
| EDP AMB ORDER SPECIFIC QUESTIONS RECORD NAME | |||||||||||||||||||
| EDP IP ORDER SPECIFIC QUESTIONS RECORD NAME | |||||||||||||||||||
| EDP IP SPECIMEN SOURCE | Blood, Venous Blood, Central Line Blood, Arterial Blood, Capillary |
||||||||||||||||||
| EDP OP SPECIMEN SOURCE | |||||||||||||||||||
| EDP IP SPECIMEN TYPE | Blood | ||||||||||||||||||
| EDP OP SPECIMEN TYPE | |||||||||||||||||||
| DERIVED EDP IP BUTTONS S | Blood, Central Line Blood, Arterial Blood, Capillary Blood, Venous |
||||||||||||||||||
| DERIVED EDP IP BUTTONS T | Blood | ||||||||||||||||||
| DERIVED EDP OP BUTTONS S | |||||||||||||||||||
| DERIVED EDP OP BUTTONS T | |||||||||||||||||||
| IP ORDERABLE | |||||||||||||||||||
| OP ORDERABLE | |||||||||||||||||||
| STANDARD LAB COMPONENTS | |||||||||||||||||||
| STANDARD LAB COMPONENTS RECORD NAME | |||||||||||||||||||
| COMPONENT DATA REQUIREMENT | |||||||||||||||||||
| EPIC OP AOEs | |||||||||||||||||||
| EPIC IP AOEs | |||||||||||||||||||
EPIC Components (results - crosswalked through Cerner)
| |||||||||||||||||||